Recently, Souweidane et al.33 reported the result of their phase 1 trial infusing radioimmunotherapy agent targeting the glioma-associated B7-H3 antigen against pediatric DIPG and demonstrated the safety and feasibility of this strategy. This evidence concerns the gene CD276 and central nervous system cancer.